Syndax Pharmaceuticals SNDX announced positive top-line results for revumenib, an oral small-molecule menin inhibitor, from the AUGMENT-101 study. The results were announced from the relapsed or ...
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback